Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 10, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Purchased: 700,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,357.57 pence per share.
- Treasury Shares Held: 239,282,678 shares (post-purchase).
- Shares in Issue: 5,753,924,665 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback program. The company acquired 700,000 shares on January 10, 2007, which are now held in Treasury. This action updates the total number of shares in issue and the total voting rights available to shareholders.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,753,924,665) for calculating ownership percentages under Financial Services Authority Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (239,282,678) for assessing potential future share buybacks or capital restructuring.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial results.